Lehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, December 23, 2025 - CancerVax, Inc., the developer of a breakthrough Universal Cancer Treatment Platform that uses the body’s immune system to treat cancer, today released a year-end summary highlighting significant advancements made throughout 2025. These achievements mark a transformative period in the Company’s development as it accelerates its mission to create safe, targeted, and broadly adaptable cancer treatments.
Throughout 2025, CancerVax achieved substantial scientific progress, expanded its leadership and intellectual property portfolio, and advanced the development of its AI-engineered "Smart mRNA" and nanoparticle delivery technologies. These accomplishments position the Company for a strong 2026 as it moves toward in-vivo studies and continued platform expansion.
Key Accomplishments Since January 2025
Strengthened Scientific Leadership- Appointed a world-class biotech executive as Chief Scientific Advisor to guide platform development and strategic execution (see source).
Engineered Precision Cell-Targeting Nanoparticles- Developed ligand-conjugated lipid nanoparticles capable of identifying cancer-specific biomarkers. Validated selective uptake into cancerous cells while avoiding healthy cells. Demonstrated functionality of dual-key targeting architecture (Marker1 + Marker2), (see source).
Expanded Platform Capability to Aggressive Liver Cancers- Initiated research programs targeting hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), (see source).
Breakthrough: Cancer Cells Successfully Disguised as Pathogens- Achieved proof-of-principle demonstrating cancer cells can be disguised as common pathogens to trigger immune attack (see source).
Filed Foundational PCT Patent Application- Submitted non-provisional PCT application protecting the universal cancer immunotherapy platform (see source).
Advanced Smart mRNA Activation Technology- Confirmed Smart mRNA remains inactive in healthy human liver cells and Smart mRNA only activates inside cancer cells, reducing off-target toxicity (see source).
Strong cancer cell uptake and Smart mRNA activation- Recent In-vitro studies showed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells, providing confidence in moving forward with animal testing (see source).
Platform Momentum and Path Toward 2026
As the Company plans for 2026, major milestones expected include: 1) Integration of nanoparticles with Smart mRNA to form full therapeutic nanoparticles. 2) Complete pre-IND animal studies to determine toxicity and efficacy in pancreatic and liver cancers. 3) Expand scientific collaborations and future IND groundwork.
CEO Statement
“Our progress in 2025 represents a turning point in the development of our universal cancer immunotherapy platform,” said Byron Elton, CEO of CancerVax. “This year, we shifted from theoretical possibility to validated scientific evidence. Our breakthroughs bring us significantly closer to delivering cancer treatments that are more precise, more accessible, and more humane.”
To learn more about the CancerVax platform, please watch the Short Explainer Video at https://cancervax.com/explainer
About CancerVax
CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases, such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot — a better way to fight cancer. To learn more, please visit www.CancerVax.com
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Press Contact:
CancerVax, Inc.
Tel: (805) 356-1810
communications@CancerVax.com
